Thyroid cancer risk and follow-up after childhood radiotherapy
Official title: Thyroid Carcinoma in Cancer Patients Undergoing Radiotherapy
Run by IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT07473518 · Data updated 2026-11-12
This project will test whether earlier and regular ultrasound plus genetic testing can detect thyroid nodules and cancers sooner in children treated with radiotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 10 Years to 43 Years |
| Sex | All |
| Enrollment | 2550 (estimated) |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Drugs / interventions | radiation |
| Locations | 2 sites (Bologna and 1 other locations) |
| Status | Recruiting |
| Started | July 30, 2025 |
| Main results expected | July 30, 2026 |
| Study ends | July 30, 2027 |
| Registry record updated | March 16, 2026 |
| Trial ID | NCT07473518 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children who received radiotherapy before age 18 (between 1999 and 2018) and have at least four years of follow-up at the IRCCS AOU Bologna pediatric endocrine program are ideal candidates.
✕Probably not a fit
Children who were never exposed to ionizing radiation or who already have genetic syndromes or autoimmune thyroid disease under existing surveillance may not derive direct benefit from radiotherapy-specific findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study follows children who received radiotherapy before age 18 and compares them with unexposed pediatric controls to determine how often and when thyroid nodules and differentiated thyroid cancer occur. Participants receive early and intensive clinical and ultrasound follow-up and available thyroid lesions undergo genetic analysis on cytology and surgical specimens to look for predictive biomarkers. Researchers will analyze incidence, timing, and risk factors to define optimal surveillance schedules that balance early detection with practicality and patient burden. The genetic findings aim to inform personalized surgical decisions and the potential use of targeted therapies in this post-radiotherapy pediatric population.
Why it matters
Potential benefit: If successful, this could enable earlier, more personalized detection and treatment—reducing unnecessary surgery for low-risk findings and improving outcomes for children who develop aggressive tumors.
How similar studies have gone: Previous work has established that childhood radiotherapy increases thyroid cancer risk, and ultrasound surveillance is commonly used, but molecular biomarker testing in this specific pediatric, post-radiotherapy group remains relatively untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
INCLUSION CRITERIA For the group of oncologic patients who underwent radiotherapy: * Radiotherapy for an oncologic condition performed between January 1, 1999, and December 31, 2018; * Age at the time of radiotherapy \< 18 years; * Follow-up of at least 4 years conducted at the Endocrine-Metabolic Diseases Program, Pediatric Unit, IRCCS AOU Bologna; * Obtained informed consent For the group of subjects not exposed to radiotherapy and without specific risk factors for DTC: * No history of exposure to ionizing radiation; * No specific risk factors for DTC (autoimmune thyroiditis, familial forms, genetic syndromes); * Thyroid ultrasound performed between January 1, 1999, and December 31, 2018, at the Nuclear Medicine Unit of IRCCS AOU Bologna; * Age at the time of the thyroid ultrasound \< 18 years; * Obtained informed consent EXCLUSION CRITERIA: For the group of oncologic patients who underwent radiotherapy: * Patients transferred to another center before completing 4 years of follow-up after radiotherapy at the Pediatric Unit of IRCCS AOU Bologna, without having received a diagnosis of thyroid cancer. For the group of subjects not exposed to radiotherapy and without specific risk factors for DTC: * None.
Where it's running
-
UO Medicina Nucleare - IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy Recruiting -
UOC Pediatria - IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy Recruiting
Study contacts
- Study coordinator: Federico Baronio
- Email: federico.baronio@aosp.bo.it
- Phone: 00390512144816
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
FaceSay: a computer program to help kids recognize facial expressions and improve social interactions
A computer-based FaceSay program is tested to see if it helps survivors of pediatric brain tumors who have social difficulties see facial expressions better and relate more comfortably with peers.
-
Access to Innovative Cancer Treatments for Children and Young People in Belgium
This observational study collects safety and effectiveness data on off‑label and compassionate cancer medicines used in kids and young adults up to age 25 in Belgium.
-
BCB-276 CAR T therapy for DIPG in children and young adults
This study tests BCB-276, a patient's own CAR T cells against DIPG, after standard radiation, to see if it is safe and can help extend survival.
-
CAYA cancer patients in LMICs: a forward-looking observation of care and outcomes
This study follows children, teens, and young adults with cancer in low- and middle-income countries to see how routine care affects treatment, access, and outcomes over time.
-
Virtual reality headsets to reduce anxiety and fear during intrathecal chemotherapy in children
This project will try virtual reality headsets with children aged 4–10 who are receiving intrathecal chemotherapy to see if they reduce anxiety, fear, and changes in vital signs.
-
Laser thermal therapy for young people with low-grade glioma
This research will test whether laser interstitial thermal therapy (LITT) can stop or slow recurrent or progressive low-grade gliomas in children, adolescents, and young adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.